<DOC>
	<DOCNO>NCT00035165</DOCNO>
	<brief_summary>This study examine whether new investigational drug EPO906 , give intravenous infusion ( IV directly vein ) , effective shrinking tumor prevent growth cell cause melanoma .</brief_summary>
	<brief_title>EPO906 Therapy Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>Inclusion Criteria The following patient may eligible study : Patients advance metastatic melanoma define poor prognosis Stage III melanoma Stage IV disease , histologically cytologically confirm least one measurable lesion include bone metastasis ( previous radiation treatment , target lesion must demonstrate progression since radiation ) Patients poor prognosis Stage III melanoma must locally advance unresectable disease measurable ( repeat histological cytological confirmation necessary time study entry previous result available question investigator 's opinion diagnosis ) Must life expectancy great three ( 3 ) month Prior immunotherapy interferon alpha adjuvant setting permit , must complete &gt; 4 week prior treatment Prior vaccine therapy permit , must complete &gt; 4 week prior treatment Patient major impairment hematological function ( red blood cell transfusion repeat evaluation study entry allow ) . Exclusion Criteria The following patient eligible study : Patients choroidal ocular melanoma Patients symptomatic CNS metastasis leptomeningeal involvement Patients renal hepatic dysfunction Patients peripheral neuropathy unresolved diarrhea great Grade 1 Patients severe cardiac insufficiency Patients take Coumadin warfarincontaining agent exception low dose Coumadin ( 1 mg less ) maintenance indwell line port Patients receive investigational compound antimelanoma vaccine within past 28 day plan receive investigational drug participate study Patients receive radiotherapy within last 4 week site reference disease assessment ( however , new progressive lesion previously irradiate field patient may use disease assessment patient must recover side effect radiotherapy ) Patients receive chemotherapy within last four week History another malignancy within 5 year prior study entry except curatively treat nonmelanoma skin cancer cervical cancer situ Patients active suspect acute chronic uncontrolled infection include abcesses fistulae HIV+ patient Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>melanoma</keyword>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>tumour</keyword>
	<keyword>malignant</keyword>
	<keyword>metastatic</keyword>
	<keyword>intravenous</keyword>
	<keyword>epothilone</keyword>
</DOC>